The “one drug fits all” approach leads to 100,000 deaths a year and $75 billion per year in the U.S. alone in excess healthcare costs. Our approach is to develop optimally effective drugs matched to a patient’s unique genetic profile. We classify patients with the same disease into smaller subpopulations, defined by genetic variations associated with the disease, drug metabolism, or both. Based on this approach, we intend to develop optimized medicines in genetically defined subpopulations that are more efficacious and with less side-effects than in a broad population. Our goal is to rapidly develop safer, more effective new drugs with less clinical risk and higher rates of product approvals. In so doing, we strive to bring a steady stream of new targeted medicines to market.